Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Express Scripts
Medtronic
Merck

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,433,646

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,433,646
Title:Methods of inhibiting growth of a neoplastic cell
Abstract: Disclosed are methods of preparing and using placentally-derived stem cells and compositions useful for the treatment of cancer. Said stem cells and compositions function through inducing a \"guided differentiation\" program in cancer cells, thereby reducing malignancy. Further extension of the invention pertains to augmenting ability of administered cells to induce differentiation through the co-administration of known differentiation inducing agents. Within the context of this disclosure, methods for inducing host responses to cancer are also described.
Inventor(s): Ichim; Thomas E. (San Diego, CA)
Assignee: XON CELLS, INC. (Germantown, MD)
Application Number:13/688,864
Patent Claims:1. A method of inhibiting growth of a neoplastic cell, the method comprising: (a) providing a cell free-placental extract made by the process comprising: (i) obtaining human placenta; (ii) homogenizing the obtained human placenta by digesting the obtained human placenta with a collagenase and a heparitinase, wherein the heparitinase digestion is at a neutral pH, the homogenization resulting in a homogenate; (iii) centrifuging said homogenate to produce a supernatant free of cellular debris; and (iv) purifying the supernatant to obtain cell free-placental extract comprising a cell differentiation-inducing fraction having a molecular weight in the range from about 10 Daltons to about 10,000 Daltons (b) directly administering said cell free-placental extract to the neoplastic cell which is selected from the group consisting of a leukemia cell, and a prostate cancer cell, thereby inhibiting growth of the neoplastic cell.

2. The method of claim 1, wherein the step (iv) of purifying comprises running the supernatant through adsorption on a C-18 column, and then filter sterilizing the purified supernatant.

3. The method of claim 1, wherein the neoplastic cell is in vivo.

4. The method of claim 1, wherein the neoplastic cell is in vitro.

5. The method of claim 1, wherein the administered cell free-placental extract is in a liposomal complex.

6. The method of claim 1, wherein a histone deacetylase inhibitor is added to the extract prior to the administration of said cell free placenta.

7. The method of claim 1, wherein the step(ii) further comprises sonicating the the homogenate.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Boehringer Ingelheim
Harvard Business School
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.